| Title : Phase 1 and pre-clinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia - Furze_2022_Br.J.Clin.Pharmacol__ |
| Author(s) : Furze RC , Molnar J , Parr NJ , Ahmad F , Henry Y , Howe D , Singh R , Toal M , Bassil AK , Bernard SG , Davis RP , Gibson A , Maller NC , Sharp C , Tough DF , Prinjha RK , Lewis HD |
| Ref : British Journal of Clinical Pharmacology , : , 2022 |
| Abstract : Furze_2022_Br.J.Clin.Pharmacol__ |
| ESTHER : Furze_2022_Br.J.Clin.Pharmacol__ |
| PubMedSearch : Furze_2022_Br.J.Clin.Pharmacol__ |
| PubMedID: 35655123 |
Furze RC, Molnar J, Parr NJ, Ahmad F, Henry Y, Howe D, Singh R, Toal M, Bassil AK, Bernard SG, Davis RP, Gibson A, Maller NC, Sharp C, Tough DF, Prinjha RK, Lewis HD (2022)
Phase 1 and pre-clinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia
British Journal of Clinical Pharmacology
:
Furze RC, Molnar J, Parr NJ, Ahmad F, Henry Y, Howe D, Singh R, Toal M, Bassil AK, Bernard SG, Davis RP, Gibson A, Maller NC, Sharp C, Tough DF, Prinjha RK, Lewis HD (2022)
British Journal of Clinical Pharmacology
: